No Data
No Data
IRIDEX Corporation (IRIX) Q1 2024 Earnings Call Transcript
IRIDEX Corporation (IRIX) Q1 2024 Earnings Call Transcript
Iridex on the Brink: Operational Losses and Funding Woes Threaten Company Viability
Express News | Stifel Maintains Hold on Iridex, Maintains $2 Price Target
Iridex Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 -31.27% Stifel → $2 Maintains Hold 08/26/2022 3.09% Stifel $5 → $3 Downgrades Buy → Hold 05/12/
Q1 2024 IRIDEX Corp Earnings Call
Analysts Offer Insights on Healthcare Companies: Iridex (IRIX), Nyxoah (NYXH) and Enliven Therapeutics (ELVN)